ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: lapatinib|DRUG: paclitaxel|DRUG: trastuzumab
Sponsor: Novartis Pharmaceuticals